Carlsquare advised Verso Capital, a Nordic private equity firm, on the sale of infrared sensor specialist Emberion to Exosens, a leading provider of advanced imaging technologies.
Emberion is a Finland- and UK-based company specializing in the design and manufacturing of innovative infrared sensors leveraging patented quantum dot imaging technology. Emberion’s technology originated from research activities at Nokia and was acquired by Verso Capital, a Nordic private equity firm with a track record of over 100 M&A transactions, and the management team to form Emberion in 2016.
Over the past years, Emberion has evolved from a material sciences company to a product company with a fully in-house designed SWIR camera offering and a strong customer base across various industries. Emberion is the only European colloidal quantum dot SWIR company with a full in-house developed technology stack, and its unique technology is protected by over 120 granted patents worldwide. Emberion was part of the Verso Capital investment portfolio, with other shareholders including Tesi and Nidoco AB.
Exosens is a French high-tech company with over 85 years of experience developing and manufacturing high-end electro-optical technologies in the field of amplification, detection, and imaging. Its product portfolio includes detection components and solutions such as advanced cameras, neutron and gamma detectors, instrument detectors, and light intensifier tubes. With more than 2,000 employees and research and production facilities across 12 sites in Europe and North America, Exosens is recognized as one of the world’s leading innovators in electro-optical technology.
This transaction marks a significant milestone for Exosens, strengthening its position as a leading provider of advanced imaging technologies across the electromagnetic spectrum. The addition of Emberion’s quantum dot-based infrared sensing capabilities expands Exosens’ portfolio into new application areas, including defense and surveillance as well as industrial settings such as semiconductor manufacturing quality control.
“Combining Emberion’s patented technology with Exosens’ existing offering, sales channel and large-volume manufacturing capability enables true large-scale global deployment of Emberion’s unique technology. We believe this acquisition provides an optimal path for Emberion to take the next growth step. Carlsquare provided extremely valuable guidance and support throughout the process, with exceptional dedication to get the deal done.” – Anssi Kariola, chairman of the board at Emberion and Managing Partner at Verso Capital
Carlsquare acted as the exclusive financial advisor to Verso Capital.
